
THERE ARE SOME THINGS YOUR PATIENTS MUST DO ALONE.



LIVING WITH DIALYSIS-RELATED CARNITINE DEFICIENCY ISN'T ONE OF THEM.

At Sigma-Tau Pharmaceuticals, we believe that quality of life is precious and that no patient should be overlooked, no matter how rare the illness. We research and produce drugs that treat rare diseases and disorders.

One example is dialysis related carnitine deficiency, which is a serious problem for some dialysis patients. The only prescription drug indicated for the treatment of carnitine deficiency in dialysis is Carnitor® (levocarnitine) Injection, made by Sigma-Tau Pharmaceuticals.

Sigma-Tau is the worldwide leader in carnitine and metabolic research. More than 20 percent of our revenue is devoted to clinical research, including dialysis and inborn metabolic diseases – a rate that exceeds the industry average. Our goal is to help you improve the lives of your patients.

Sigma-Tau Pharmaceuticals – helping to ensure no patient is overlooked.

For more information about Sigma-Tau, visit our Web site at www.sigmatau.com or call 1-800-447-0169.

Adverse events reported with Carnitor use include nausea, vomiting, body odor, gastritis and seizures. There are no reported contraindications or warnings. Only the intravenous form of levocarnitine is indicated for use in ESRD patients on hemodialysis. See Precautions in the Brief Summary.

